Article Text

PDF
Severe bronchospasm associated with rituximab for refractory Churg–Strauss syndrome
  1. M-A Bouldouyre,
  2. P Cohen,
  3. L Guillevin
  1. Department of Internal Medicine, French Vasculitis Study Group, Hôpital Cochin, Université Paris 5–René Descartes, Paris, France
  1. Dr M-A Bouldouyre, Department of Internal Medicine, French Vasculitis Study Group, Hôpital Cochin, Université Paris 5–René Descartes, Paris, France; marie-anne.bouldouyre{at}cch.aphp.fr

Statistics from Altmetric.com

Rituximab is now used to control antineutrophil cytoplasm antibody (ANCA)-associated vasculitides, eg, Wegener’s granulomatosis.1 2 In Churg–Strauss syndrome (CSS), a small-vessel systemic vasculitis with asthma and eosinophilia, 39% of patients have ANCA.3 4 Rituximab could be effective in ANCA-associated vasculitides, even if ANCA are not present at the time of prescription, because B lymphocytes also play a role as antigen-presenting cells and can modulate the immune response in another way than targeting antibody production. Therapy-refractory CSS5 was successfully treated with rituximab in three patients.68 We would like to draw attention to the potential risk of rituximab-associated bronchospasm, by reporting …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.